Incyte brings Phase 3 tafasitamab data to ASCO 2026, but will frontMIND reshape first-line DLBCL treatment?
Incyte’s Phase 3 tafasitamab data are headed to ASCO 2026. Read what frontMIND could change for first-line DLBCL and what risks still remain.
Pharma & Biotech
Pharma & Biotech
Obsidian Therapeutics puts OBX-115 in the spotlight, but is this a real melanoma cell therapy inflection point?
Obsidian Therapeutics will present OBX-115 melanoma data at ASCO 2026. Read why the update matters for TIL therapy, scalability, and solid tumor strategy.
Pharma & Biotech
Is botensilimab finally ready for a bigger melanoma spotlight? Agenus bets on ASCO 2026
Agenus will unveil first Phase 2 botensilimab melanoma data at ASCO 2026. Read why the update could reshape sentiment around its checkpoint platform.
Pharma & Biotech
Imneskibart enters the ASCO spotlight as Aulos Bioscience tests a smarter IL-2 strategy in melanoma
Aulos Bioscience will present new imneskibart melanoma data at ASCO 2026. Read what it could mean for IL-2 therapy and immuno-oncology.
Pharma & Biotech
From lorlatinib to PF-08634404, how Pfizer is trying to reshape its oncology story at ASCO 2026
Pfizer’s ASCO 2026 oncology data span lorlatinib, talazoparib, tucatinib and new pipeline assets. Read what the updates could change next.
Pharma & Biotech
ASCO 2026: Tubulis set to present maturing Phase I/IIa data on TUB-040 exatecan ADC in PROC
Tubulis presents updated TUB-040 Phase I/IIa data at ASCO 2026. Here is what the NAPISTAR 1-01 readout means for NaPi2b and ovarian cancer treatment.
Pharma & Biotech
ROSELLA trial at ASCO 2026: Corcept’s Lifyorli subgroup data and what it means for platinum-resistant ovarian cancer practice
Corcept presents Lifyorli ROSELLA phase 3 overall survival data by prior taxane use at ASCO 2026. What the subgroup analysis means for prescribers, payers, and the EMA review. Read now.
Pharma & Biotech
AVZO-021 at ASCO 2026: what updated Phase 1 results could reveal about Avenzo Therapeutics’ CDK2 strategy
Avenzo Therapeutics will present updated AVZO-021 Phase 1 data at ASCO 2026. Read why the CDK2 story could matter for breast cancer and beyond.
Pharma & Biotech
Can SIM0505’s Fast Track designation reshape the development outlook for NextCure, Inc. in ovarian cancer?
Can SIM0505’s Fast Track win accelerate NextCure’s ovarian cancer strategy? Read the full PDN analysis on risks, ASCO data, and regulatory outlook.